The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | Exciting results for BCMA/CD3 bispecific elranatamab (PF-3135) in R/R MM
Elranatamab (PF-3135) is a bispecific, humanized, monoclonal antibody consisting of BCMA and CD3-targeting arms paired on an IgG2a backbone by hinge-mutation technology. Noopur Raje, MD, Massachusetts General Hospital, Boston, MA, discusses the dose-escalation portion of an ongoing phase I study (NCT03269136) of PF-3135 in patients with relapsed/refractory multiple myeloma (MM). Early data show that treatment with intravenous PF-3135 was well tolerated at the dose levels evaluated. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
